Results We identified 15 patients currently receiving BEL therapy. Of these, 9 were not analysed further because they had no history of LN or NPSLE.

One 48-y/o female patient after renal transplantation with background therapy consisting of prednisone (GC), hydroxychloroquine (HCQ), leflunomide (LEF) and tacrolimus (TAC) had a stable disease but no additional benefit (BEL stopped after 5 months). Three female patients with GC, HCQ and mycophenolate mofetil (MMF) had an improvement of proteinuria, steroid dosage and overall quality of life. One female patient is receiving BEL or placebo (PBO) during a clinical trial (BLISS-LN), she has markedly improved proteinuria with GC, HCQ, MMF and BEL/PBO. One 73-y/o male patient with NPSLE who failed or could not tolerate various standard and additional therapies (including Rituximab and Cyclophosphamide) had a persistent clinical improvement of cutaneous lupus and neuropsychiatric symptoms (dysarthria, concentration, ataxia) after the second BEL infusion. Overall, there was one upper respiratory tract infection but no other adverse events.

Conclusions In the six patients analysed, 3 had improved proteinuria, 1 had stable disease after renal transplantation, 1 improved regarding NPSLE symptoms and 1 had improved proteinuria, but in the last case, it is not yet clear whether the effect is due to BEL. Overall, while the results of the BLISS-LN trial are awaited, we experienced improved Lupus nephritis with BEL in addition to standard therapy and observed one case of improved NPSLE. While BEL has not been approved for these severe organ manifestations, it still might be effective in well-selected patients.

Dyslipidemia is a well-established atherosclerotic risk factor. It is also believed to affect the outcome of SLE, especially in lupus nephritis patients (LN). The aim of this study was to assess the prevalence and impact of dyslipidemia in our LN patients.

Methods We performed a retrospective clinical study, 140 patients with biopsy-proven LN from were analysed. The renal activity and classification were evaluated according to renal pathology. SLE disease activity was scored using the SLE Disease Activity Index (SLEDAI). Adverse outcome was defined by the occurrence of ESRD or death. The correlations between dyslipidemia and both ESRD and mortality were assessed.

Results Mean age of our patients was 34.63±12.7 years old, 83% were females. Class III, IV and V lupus nephritis accounted for 21%, 58.7% and 11.2%. The prevalence of dyslipidemia with elevations in total cholesterol (TC), low-density lipoprotein (LDL), triglyceride (TG) was noted in our LN patients, ranging from 41% at diagnosis to 59.7% or even higher after 24 months, and statins were administered in 23% of the patients.

After a mean follow-up of 22 months, ESRD occurred in 24%, and death in 13% of cases. Moreover, dyslipidemia was significantly associated to both ESRD (p<0.02) and death (p<0.003).
Conclusions Dyslipidemia is a significant comorbidity of LN that severely affects its renal and overall outcome. Its treatment represents a modifiable risk factor; adequate management can decrease its complications in LN patients and therefore improve their overall morbidity and mortality.

<table>
<thead>
<tr>
<th>PS8:170</th>
<th>LUPUS NEPHRITIS IN A MULTI-ETHNIC COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM BERKSHIRE, UK</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. Gindea, S. Williams, Frimley Health Foundation Trust – Department of Rheumatology, Slough, UK</td>
<td></td>
</tr>
<tr>
<td>10.1136/lupus-2018-abstract.213</td>
<td></td>
</tr>
</tbody>
</table>

Background Previous studies suggest that ethnicity influences the clinical phenotype in systemic lupus erythematosus (SLE), with lupus nephritis (LN) being more frequent in non-Caucasians. However, there are scarce data regarding prevalence of LN in South-Asian population (Indians, Pakistanis, Sri Lanka, or Bangladeshis).

Objectives This study aimed to compare the prevalence of LN between lupus patients of different ethnicities, and to compare demographics and disease characteristics between LN patients.

Methods This is a retrospective chart review study of 100 lupus patients followed from 2013 to 2017 at Wexham Park Hospital, a large district hospital in Southern England. The patients were categorised into four ethnic groups Caucasians, South-Asians, Blacks and Others (mixed race, Orientals, Arabs). LN prevalence, demographic and clinical data were compared using Fisher/Chi-Square tests for categorical variables and Wilcoxon test for continuous variables.

Results Of 100 patients in the study sample, 51% were Caucasians, 31% were South-Asians, 11% were Blacks and 7% had other ethnicities. Mean age was 48 yo and 90% were females. Prevalence of LN was 26% in the full study sample and 24%, 16%, 64% and 57%, respectively, among Caucasians, South-Asians, Blacks and Others. LN prevalence was significantly lower in South-Asians vs Blacks (p=0.01), South-Asians vs Blacks (<0.01) and South-Asians vs Other (p=0.02). Among patients with LN, mean age was lower in South-Asians and Blacks, than Caucasians and Others (44 and 45 yo vs 52 and 51 yo). Blacks appear to include more males (43% vs <25% in the other groups). Renal biopsy, available for 22/26 LN patients, suggested Class II predominance in Caucasians (44%) vs 33% in the other groups). Proliferative LN (Class III and IV) was confirmed in 7 patients, without significant predominance in any ethnic group. Specific lupus autoantibodies (anti-dsDNA Ab and/or antiSm Ab) were found in 64% Caucasians, 75% south-Asians, 86% Blacks and 75% others with LN.

Conclusion In our cohort, prevalence of LN in South-Asians was lower than in Blacks, but not statistically different comparing with Caucasians. However, South-Asians and Blacks with LN were younger than Caucasians. These results should be re-examined in larger similar multi-ethnic cohorts.